Market: NASD |
Currency: USD
Address: 245 First Street, Riverview II
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
📈 Cyclerion Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.050000 |
- |
2023-05-16 |
- |
Stock split |
|
Total Amount for 2023: $0.050000 |
📅 Earnings & EPS History for Cyclerion Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2022-11-03 | -4.8 |
| 2022-08-09 | -6.2 |
| 2022-05-04 | -6 |
| 2022-02-24 | -3.82 |
| 2021-11-09 | -5.2 |
| 2021-02-25 | -11 |
| 2020-11-05 | -11.8 |
| 2020-08-03 | -14 |
| 2020-05-04 | -14.6 |
| 2020-03-12 | -19 |
| 2019-11-12 | -20 |
| 2019-08-12 | -23.6 |
📰 Related News & Research
No related articles found for "cyclerion therapeutics".
